By Tom Rosenthal
Rates of virologic suppression and immunologic response increased from weeks 48 to 96 in a phase 3 clinical trial evaluating the safety and efficacy of fostemsavir (ViiV Healthcare) for a difficult-to-treat population with multi-drug-resistant HIV-1, according to findings presented at the 2019 International AIDS Society Conference of HIV Science (IAS 2019), in Mexico City.